APG Asset Management N.V. Has $9.92 Million Stock Position in Hologic, Inc. $HOLX

Key Points

• APG Asset Management N.V. has reduced its stake in Hologic, Inc. by 9.9%, selling 19,067 shares and now holding 173,439 shares worth approximately $9,918,000.
• Hologic's stock price recently opened at $67.13, showing a 1.7% decline, with a market capitalization of $14.93 billion.
• The company reported quarterly earnings of $1.08 per share, exceeding analyst estimates, and has issued guidance expecting Q4 2025 earnings between 1.090-1.120 EPS.

APG Asset Management N.V. lowered its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 9.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 173,439 shares of the medical equipment provider's stock after selling 19,067 shares during the period. APG Asset Management N.V. owned about 0.08% of Hologic worth $9,918,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Beverly Hills Private Wealth LLC raised its stake in Hologic by 3.6% during the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock worth $320,000 after buying an additional 180 shares during the last quarter. Allworth Financial LP raised its stake in Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after buying an additional 216 shares during the last quarter. Dark Forest Capital Management LP raised its stake in Hologic by 7.9% during the fourth quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock worth $220,000 after buying an additional 223 shares during the last quarter. Baker Avenue Asset Management LP raised its stake in Hologic by 0.5% during the fourth quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock worth $3,031,000 after buying an additional 225 shares during the last quarter. Finally, Integrated Advisors Network LLC raised its stake in Hologic by 5.4% during the first quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider's stock worth $346,000 after buying an additional 289 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Evercore ISI lifted their target price on shares of Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research note on Tuesday, July 8th. Argus raised shares of Hologic from a "hold" rating to a "buy" rating and set a $80.00 target price for the company in a research note on Monday, August 18th. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and lifted their price target for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Finally, Wall Street Zen downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $78.00.

Hologic Stock Up 0.8%

Shares of NASDAQ HOLX traded up $0.50 during mid-day trading on Friday, reaching $67.12. 1,080,191 shares of the company's stock traded hands, compared to its average volume of 1,681,669. The stock has a market cap of $14.93 billion, a P/E ratio of 27.85, a PEG ratio of 2.44 and a beta of 0.57. The business has a 50-day simple moving average of $66.15 and a 200 day simple moving average of $62.49. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business's revenue was up 1.2% on a year-over-year basis. During the same period last year, the company earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.